GPCR NewsJan 1, 20221 min readGPCR PapersAddex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesiaJanuary 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator...